A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Key facts

Sponsor

MedImmune LLC

Principal Investigator

MedImmune, LLC MedImmune, LLC

MedImmune LLC

Intervention

Tremelimumab(biological)

Enrollment

433 target

Eligibility

18-99 years · All sexes

Timeline

2015 – 2026

Study locations (30)

• Research Site, Phoenix, Arizona, United States
• Research Site, San Francisco, California, United States
• Research Site, New Haven, Connecticut, United States
• Research Site, Jacksonville, Florida, United States
• Research Site, Tampa, Florida, United States
• Research Site, Indianapolis, Indiana, United States
• Research Site, Boston, Massachusetts, United States
• Research Site, New York, New York, United States
• Research Site, Stony Brook, New York, United States
• Research Site, Durham, North Carolina, United States
• Research Site, Portland, Oregon, United States
• Research Site, Philadelphia, Pennsylvania, United States
• Research Site, Nashville, Tennessee, United States
• Research Site, Dallas, Texas, United States
• Research Site, Seattle, Washington, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06902246
  Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
  University of Miami
• RECRUITINGPHASE1NCT07419841
  A Phase 1 Study of the Safety and Tolerability of CTX-10726
  Compass Therapeutics
• RECRUITINGPHASE1NCT07493044
  An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
  Guangzhou FineImmune Biotechnology Co., LTD.
• RECRUITINGPHASE2NCT07122089
  Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
  Center Eugene Marquis
• RECRUITINGPHASE1, PHASE2NCT07482059
  A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
  West China Hospital
• RECRUITINGPHASE2NCT06254248
  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNANCT07469319
  Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
  University of Aarhus
• RECRUITINGEARLY PHASE1NCT07242417
  TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
  Beijing GoBroad Hospital

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma →